Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9

Journal of Medicinal Chemistry

Volumn 50, Issue 6, 2007, Pages 1158-1165

  Locuson, Charles W ^a   Gannett, Peter M ^b   Ayscue, Robyn ^b   Tracy, Timothy S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 INHIBITOR; DAPSONE; DAPSONE DERIVATIVE; ENZYME ACTIVATOR;

ALLOSTERISM; ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME KINETICS; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; NONHUMAN;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; DAPSONE; DATABASES, FACTUAL; ENZYME ACTIVATORS; ENZYME INHIBITORS; FLURBIPROFEN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NADPH-FERRIHEMOPROTEIN REDUCTASE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS;

EID: 33947705581     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060706p     Document Type: Article

References (40)

1. Evans, W. E.; Relling, M. V. Moving towards individualized medicine with pharmacogenomics. Nature 2004, 429, 464-468.
2. Bachmann, K. A. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr. Drug Metab. 2006, 7, 1-14.
3. Wienkers, L. C.; Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discovery 2005, 4, 825-833.
4. Atkins, W. M. Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 291-310.
5. Tracy, T. S.; Hummel, M. A. Modeling kinetic data from in vitro drug metabolism enzyme experiments. Drug Metab. Rev. 2004, 36, 231-242.
6. Dabrowski, M. J.; Schrag, M. L.; Wienkers, L. C.; Atkins, W. M. Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J. Am. Chem. Soc. 2002, 124, 11866-11867.
7. Hummel, M. A.; Gannett, P. M.; Aguilar, J. S.; Tracy, T. S. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry 2004, 43, 7207-7214.
8. Rock, D. A.; Perkins, B. N.; Wahlstrom, J.; Jones, J. P. A method for determining two substrates binding in the same active site of cytochrome P450BM3: an explanation of high energy omega product formation. Arch. Biochem. Biophys. 2003, 416, 9-16.
9. Locuson, C. W.; Gannett, P. M.; Tracy, T. S. Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9. Arch. Biochem. Biophys. 2006, 449, 115-129.
10. Hutzler, J. M.; Frye, R. F.; Korzekwa, K. R.; Branch, R. A.; Huang, S. M.; Tracy, T. S. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur. J. Pharm. Sci. 2001, 14, 47-52.
11. Liu, K. H.; Kim, M. J.; Jung, W. M.; Kang, W.; Cha, I. J.; Shin, J. G. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab. Dispos. 2005, 33, 209-213.
12. Shoichet, B. K.; McGovern, S. L.; Wei, B.; Irwin, J. J. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 2002, 6, 439-446.
13. Dabrowski, M. J.; Schrag, M. L.; Wienkers, L. C.; Atkins, W. M. Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J. Am. Chem. Soc. 2002, 124, 11866-11867.
14. Hummel, M. A.; Gannett, P. M.; Aguilar, J. S.; Tracy, T. S. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry 2004, 43, 7207-7214.
15. Rock, D. A.; Perkins, B. N.; Wahlstrom, J.; Jones, J. P. A method for determining two substrates binding in the same active site of cytochrome P450BM3: an explanation of high energy omega product formation. Arch. Biochem. Biophys. 2003, 416, 9-16.
16. Hutzler, J. M.; Kolwankar, D.; Hummel, M. A.; Tracy, T. S. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab. Dispos. 2002, 30, 1194-1200.
17. Hutzler, J. M.; Kolwankar, D.; Hummel, M. A.; Tracy, T. S. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab. Dispos. 2002, 30, 1194-1200.
18. Egnell, A. C.; Eriksson, C.; Albertson, N.; Houston, B.; Boyer, S. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J. Pharmacol. Exp. Ther. 2003, 307, 878-887.
19. Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J. Biol. Chem. 2004, 279, 35630-35637.
20. Gotoh, O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 1992, 267, 83-90.
21. Kumar, V.; Locuson, C. W.; Sham, Y. Y.; Tracy, T. S. Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles. Drug Metab. Dispos. 2006, 34, 1688-1696.
22. Bland, T. M.; Haining, R. L.; Tracy, T. S.; Gallery, P. S. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem. Pharmacol. 2005, 70, 1096-1103.
23. Ekroos, M.; Sjogren, T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13682-13687.
24. Irwin, J. J.; Shoichet, B. K. ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 45, 177-182.
25. Torimoto, N.; Ishii, I.; Hata, M.; Nakamura, H.; Imada, H.; Ariyoshi, N.; Ohmori, S.; Igarashi, T.; Kitada, M. Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. Biochemistry 2003, 42, 15068-15077.
26. Ashida, T.; Hirokawa, S. The crystal structure of a-pyridoin, 1,2-di-2-pyridylethenediol-1,2. Acta Crystallogr. 1965, 18, 122-127.
27. Nagano, S.; Poulos, T. L. Crystallographic study on the dioxygen complex of wild-type and mutant cytochrome P450cam. Implications for the dioxygen activation mechanism. J. Biol. Chem. 2005, 280, 31659-31663.
28. Gotoh, O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. 1992, 267, 83-90.
29. Egnell, A. C.; Eriksson, C.; Albertson, N.; Houston, B.; Boyer, S. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J. Pharmacol. Exp. Ther. 2003, 307, 878-887.
30. Tracy, T. S.; Hutzler, J. M.; Haining, R. L.; Rettie, A. E.; Hummel, M. A.; Dickmann, L. J. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab. Dispos. 2002, 30, 385-390.
31. Irwin, J. J.; Shoichet, B. K. ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 45, 177-182.
32. Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J. Biol. Chem. 2004, 279, 35630-35637.
33. Case, D. A.; Darden, T. A.; Cheatham, I. T. E.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Wang, B.; Pearlman, D. A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, C.; Caldwell, J. W.; Ross, W. S.; Kollman, P. A. University of California, San Francisco. AMBER 8 2004.
34. Cornell, W.; Cieplak, P.; Bayly, C.; Gould, L.; Merz, K., Jr.; Ferguson, D.; Spellmeyer, D.; Fox, T.; Caldwell, J.; Kollman, P. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1999, 117, 5179-5197.
35. Simmerling, C.; Elber, R.; Zhang, J. MOIL-View - A program for visualization of structure and dynamics of biomolecules and STO - A program for computing stochastic paths. In Modeling of biomolecular structure and mechanisms; Pullman, A., Ed.; Kluwer: Netherlands, 1995; pp 241-265.
36. de Graaf, C.; Pospisil, P.; Pos, W.; Folkers, G.; Vermeulen, N. P. Binding mode prediction of cytochrome p450 and thymidine kinase protein-ligand complexes by consideration of water and rescoring in automated docking. J. Med. Chem. 2005, 48, 2308-2318.
37. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
38. Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J. Biol. Chem. 2004, 279, 35630-35637.
39. Hutzler, J. M.; Kolwankar, D.; Hummel, M. A.; Tracy, T. S. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab. Dispos. 2002, 30, 1194-1200.
40. Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J. Biol. Chem. 2004, 279, 35630-35637.